Michael Sebag

Dr. Michael Sebag’s research focuses on the second most common hematologic malignancy in adults, multiple myeloma. He focuses on bench to bedside research with emphasis on both basic science and clinical trials in multiple myeloma. In the lab, his team is focusing on the impact of the microenvironment on the development and progression of multiple myeloma. They are looking at the role of the multiple myeloma cell in osteoblastic development and its impact on multiple myeloma bone disease. They are also working on novel agents which target either the myeloma cell directly or its microenvironment with the aid of a novel transgenic model of multiple myeloma.